Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ASCO's Richard Schilsky On State-of-the-Art Oncology Trials

Executive Summary

ASCO's chief medical officer Richard Schilsky discusses innovative clinical trial designs in oncology, challenges facing developers of cancer combination therapies and future developments for the society's value frameworks.

You may also be interested in...



Oncology Drug Value Tools From NCCN, ASCO To Get Real-World Testing

Officials from oncology professional organizations discuss next steps in the development of their frameworks for valuing oncology drugs.

Genomics-Driven Trials Built To Be Fast And Flexible

Pioneering enrollment strategies are coupled with adaptive statistical designs in the next wave of basket trials from NCI, ASCO and Novartis.

Cancer Trials & Tribulations: Combinations Are Easier Said Than Done

Combinations of checkpoint inhibitors and targeted drugs are said to hold the key to better, more durable results in the future. But recent studies highlighted some big challenges, like unexpected toxicities, prompting a call for more preclinical research to better predict winning combinations.

Related Content

Topics

UsernamePublicRestriction

Register

SC099693

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel